171 related articles for article (PubMed ID: 24121426)
1. Synergistic protective effects of mizoribine and angiotensin II receptor blockade on cyclosporine A nephropathy in rats.
Endo A; Someya T; Nakagawa M; Murano Y; Sakuraya K; Hara S; Fujinaga S; Ohtomo Y; Murakami H; Shimizu T
Pediatr Res; 2014 Jan; 75(1-1):38-44. PubMed ID: 24121426
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of Mizoribine on Cyclosporine A nephropathy in rats.
Hara S; Umino D; Someya T; Fujinaga S; Ohtomo Y; Murakami H; Shimizu T
Pediatr Res; 2009 Nov; 66(5):524-7. PubMed ID: 19668109
[TBL] [Abstract][Full Text] [Related]
3. Influence of cyclosporine A on glomerular growth and the effect of mizoribine and losartan on cyclosporine nephrotoxicity in young rats.
Kim JH; Lee YH; Lim BJ; Jeong HJ; Kim PK; Shin JI
Sci Rep; 2016 Mar; 6():22374. PubMed ID: 26947764
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy.
Yang CW; Ahn HJ; Kim WY; Li C; Jung JY; Yoon SA; Kim YS; Cha JH; Kim J; Bang BK
Transplantation; 2003 Feb; 75(3):309-15. PubMed ID: 12589150
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.
Pérez-Rojas J; Blanco JA; Cruz C; Trujillo J; Vaidya VS; Uribe N; Bonventre JV; Gamba G; Bobadilla NA
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F131-9. PubMed ID: 16835406
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity.
Yang CW; Ahn HJ; Kim WY; Li C; Kim HW; Choi BS; Cha JH; Kim YS; Kim J; Bang BK
Kidney Int; 2002 Jul; 62(1):20-30. PubMed ID: 12081560
[TBL] [Abstract][Full Text] [Related]
7. Effect of FTY720 on chronic cyclosporine nephropathy in rats.
Kim JY; Lim SW; Li C; Kim JS; Ahn KO; Yang HJ; Choi BS; Kim YS; Kim J; Bang BK; Yang CW
Transplantation; 2005 Nov; 80(9):1323-30. PubMed ID: 16314802
[TBL] [Abstract][Full Text] [Related]
8. Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity.
Padi SS; Chopra K
Pharmacol Res; 2002 May; 45(5):413-20. PubMed ID: 12123630
[TBL] [Abstract][Full Text] [Related]
9. Sodium depletion enhances fibrosis and the expression of TGF-beta1 and matrix proteins in experimental chronic cyclosporine nephropathy.
Shihab FS; Andoh TF; Tanner AM; Bennett WM
Am J Kidney Dis; 1997 Jul; 30(1):71-81. PubMed ID: 9214404
[TBL] [Abstract][Full Text] [Related]
10. Reversibility of chronic cyclosporine nephropathy in rats after withdrawal of cyclosporine.
Li C; Yang CW; Kim WY; Jung JY; Cha JH; Kim YS; Kim J; Bennett WM; Bang BK
Am J Physiol Renal Physiol; 2003 Feb; 284(2):F389-98. PubMed ID: 12529276
[TBL] [Abstract][Full Text] [Related]
11. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction.
Islam M; Burke JF; McGowan TA; Zhu Y; Dunn SR; McCue P; Kanalas J; Sharma K
Kidney Int; 2001 Feb; 59(2):498-506. PubMed ID: 11168932
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.
Feria I; Pichardo I; Juárez P; Ramírez V; González MA; Uribe N; García-Torres R; López-Casillas F; Gamba G; Bobadilla NA
Kidney Int; 2003 Jan; 63(1):43-52. PubMed ID: 12472767
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
Sun QL; Li M; Rui HL; Chen YP
J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):301-10. PubMed ID: 25500744
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.
Shihab FS; Bennett WM; Tanner AM; Andoh TF
Kidney Int; 1997 Sep; 52(3):660-73. PubMed ID: 9291185
[TBL] [Abstract][Full Text] [Related]
15. Blockade of angiotensin II with losartan attenuates transforming growth factor-beta1 inducible gene-h3 (betaig-h3) expression in a model of chronic cyclosporine nephrotoxicity.
Sun BK; Li C; Lim SW; Choi BS; Lee SH; Kim IS; Kim YS; Bang BK; Yang CW
Nephron Exp Nephrol; 2005; 99(1):e9-16. PubMed ID: 15637465
[TBL] [Abstract][Full Text] [Related]
16. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity.
Shihab FS; Yi H; Bennett WM; Andoh TF
Kidney Int; 2000 Sep; 58(3):1174-85. PubMed ID: 10972680
[TBL] [Abstract][Full Text] [Related]
17. Polymerized type I collagen reduces chronic cyclosporine nephrotoxicity.
Sánchez-Pozos K; Lee-Montiel F; Pérez-Villalva R; Uribe N; Gamba G; Bazan-Perkins B; Bobadilla NA
Nephrol Dial Transplant; 2010 Jul; 25(7):2150-8. PubMed ID: 20139407
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin.
Pichler RH; Franceschini N; Young BA; Hugo C; Andoh TF; Burdmann EA; Shankland SJ; Alpers CE; Bennett WM; Couser WG
J Am Soc Nephrol; 1995 Oct; 6(4):1186-96. PubMed ID: 8589285
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine nephropathy: pathophysiology and clinical impact.
Shihab FS
Semin Nephrol; 1996 Nov; 16(6):536-47. PubMed ID: 9125798
[TBL] [Abstract][Full Text] [Related]
20. Change from cyclosporine to combination therapy of mycophenolic acid with the new sphingosine-1-phosphate receptor agonist, KRP-203, prevents host nephrotoxicity and transplant vasculopathy in rats.
Fujishiro J; Suzuki C; Kudou S; Yasue T; Hakamata Y; Takahashi M; Murakami T; Hashizume K; Kobayashi E
J Heart Lung Transplant; 2006 Jul; 25(7):825-33. PubMed ID: 16818126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
